SCHEDULE: Foresite Capital Discloses 5.1% Stake in Verastem

Foresite Capital Fund VI LP, Foresite Capital Management VI, LLC, and James Tananbaum have reported a 5.1% beneficial ownership in Verastem, Inc. common stock.

Summary

• Foresite Capital Fund VI LP, Foresite Capital Management VI, LLC, and James Tananbaum (collectively, 'Reporting Persons') have filed a Schedule 13G.
• The Reporting Persons beneficially own 3,135,120 shares of Verastem, Inc. Common Stock.
• This represents 5.1% of Verastem, Inc.'s outstanding Common Stock.
• The percentage is calculated based on 61,545,270 shares outstanding as of August 7, 2025, as reported in Verastem's Form 10-Q.
• The filing indicates a passive investment, with no intent to change or influence control of the issuer.

Sentiment

Score: 6

Explanation: The disclosure of a significant passive stake by an institutional investor like Foresite Capital is generally viewed as a positive signal of confidence in the company, though it provides no operational or financial performance details.

Positives

• A significant institutional investor, Foresite Capital, has taken a 5.1% stake in Verastem, Inc., potentially signaling confidence in the company's prospects and long-term value.

Future Outlook

The filing is a disclosure of beneficial ownership and does not contain forward-looking statements or guidance regarding Verastem, Inc.'s future performance or strategic direction.

Industry Context

The investment by Foresite Capital, a venture capital firm focused on healthcare and life sciences, suggests continued investor interest in the biotechnology sector, particularly in companies like Verastem, Inc. This type of passive institutional investment is common for emerging biotech firms.

Stakeholder Impact

• Shareholders: Increased institutional ownership may be perceived positively, potentially enhancing investor confidence and liquidity.

Key Dates

Recommendation

The filing indicates a significant passive investment by Foresite Capital, a reputable firm, in Verastem, Inc. While this signals institutional confidence, the Schedule 13G itself does not provide operational or financial performance data to warrant a 'buy' or 'sell' recommendation. Investors should 'hold' and monitor future company performance and additional disclosures.

Keywords

Verastem Inc., Foresite Capital, Schedule 13G, Institutional Ownership, Common Stock, Biotechnology Investment, Passive Investment